International journal of drug discovery and pharmacology最新文献

{"title":"New Tale of Metformin in Cardio-Oncology","authors":"X. Wang","doi":"10.53941/ijddp.0201001","DOIUrl":"https://doi.org/10.53941/ijddp.0201001","url":null,"abstract":"Editorial\u0000New Tale of Metformin in Cardio-Oncology\u0000\u0000Xin Wang ,\u0000\u0000\u0000Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, M139PT Manchester, UK.\u0000* Correspondence: xin.wang@manchester.ac.uk\u0000","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73491682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Minimally Invasive Approach for Cardiac Electrophysiology Studies in Mice","authors":"M. Zi, S. Abraham, A. D’Souza, D. Hutchings, S. Prehar, Xin Wang, E. Cartwright","doi":"10.53941/ijddp.0201006","DOIUrl":"https://doi.org/10.53941/ijddp.0201006","url":null,"abstract":"Review\u0000A Minimally Invasive Approach for Cardiac Electrophysiology Studies in Mice\u0000\u0000Min Zi , * , Sabu Abraham , Alicia D'souza , David Hutchings , Sukhpal Prehar , Xin Wang , and Elizabeth J Cartwright\u0000\u0000\u0000Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, United Kingdom\u0000* Correspondence: min.zi@manchester.ac.uk\u0000 \u0000 \u0000Received: 6 January 2023\u0000Accepted: 9 February 2023\u0000Published: 25 March 2023\u0000 \u0000\u0000Abstract: Atrial fibrillation and ventricular tachycardia are commonly seen in clinic. Different approaches have been developed to investigate underlying mechanisms. Transvenous approach (TA) is widely used for studies but has several drawbacks. We therefore developed a novel minimally invasive approach (MIA) for mechanistic studies. Study included 27 male C57BL/6J mice, 19 for MIA and 8 for TA. Under general anaesthesia, ECG was recorded. A key hole was made on the right first intercostal space by separating the intercostal muscles, followed by the exposure of the superior vena cava and the top of the atrium. An EPR-800 catheter was inserted vertically, perpendicular to the chest, for atrial pacing and flatly over the ventricles for ventricular pacing. Burst S1–S1 and decremental S1–S2 pacing protocols were performed to evaluate SA recovery time (SNRT), the atrioventricular node effective refractory period (AVN-ERP), Wenckebach period, ventricular ERP, and arrhythmia susceptibility. MIA was successfully performed in all 19 mice without any complications. One mouse died during TA due to venous rupture. Compared MIA with TA, surgical time were significantly shorter (P<0.0001). Wenckebach period was shorter as well (P<0.05). No difference was found in baseline sinus cycle length, SNRT, correct SNRT, AVN-ERP, ventricular ERP, and arrhythmia susceptibility (all P>0.05). The novel MIA outplays TA by providing similar outcomes of PES but consuming less time, demanding less surgical expertise, and reducing the potential of surgical complications. Given the minimal tissue injury, it also provides great potential as a recovery procedure for longitudinal study.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"133 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87208815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Protein Expression Using Nucleic Acid Therapeutics","authors":"G. Hu, Chen Chen","doi":"10.53941/ijddp.0201002","DOIUrl":"https://doi.org/10.53941/ijddp.0201002","url":null,"abstract":"Review\u0000Promising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Protein Expression Using Nucleic Acid Therapeutics\u0000\u0000Guo Hu  and Chen Chen *\u0000\u0000\u0000Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.\u0000* Correspondence: chenchen@tjh.tjmu.edu.cn; Tel. & Fax: 86-27-6937-8422\u0000 \u0000 \u0000Received: 10 October 2022\u0000Accepted: 4 November 2022\u0000Published: 11 January 2023\u0000 \u0000\u0000Abstract: Duchenne muscular dystrophy is caused by inadequate generation of functional dystrophin protein. Traditional clinical treatments can only slightly mitigate the progression of the disease, but not completely stem or reverse the decline in muscle function. Therapies aimed at dystrophin recovery are currently under development, among which are exon skipping and stop codon readthrough therapies. They are now used in clinics, while gene addition therapies are in phase III clinical trials. Gene editing therapies have also been approved for the first clinical trial recently. This review will discuss these emerging therapies, clinical trials, and directions for future developments.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80762766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological Functions and Applications of Exosomes in Drug Research","authors":"Mengmeng Fu, Jiapeng Li, Tungalag Battulga, Xiaoxue Li, Ming Xu","doi":"10.53941/ijddp.0201008","DOIUrl":"https://doi.org/10.53941/ijddp.0201008","url":null,"abstract":"Review\u0000Biological Functions and Applications of Exosomes in Drug Research\u0000\u0000Mengmeng Fu 1, Jiapeng Li 1, Tungalag Battulga 2, Xiaoxue Li 3, *, and Ming Xu 1, *\u0000\u0000\u00001 Department of Clinical Pharmacy, School of Preclinical Medicine and Clinical Pharmacy, China Pharmaceutical University, 24 Tong jia Lane, Nanjing 210009, China.\u00002 School of Pharmacy, Mongolian National University of Medical Sciences, Ulaanbaatar-24210, Mongolia.\u00003 Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.\u0000* Correspondence: lxx84112@163.com(Xiaoxue Li); mingxu@cpu.edu.cn; Tel.: 025-86185653(Ming Xu)\u0000 \u0000 \u0000Received: 9 October 2022\u0000Accepted: 12 November 2022\u0000Published: 11 January 2023\u0000 \u0000\u0000Abstract: Exosomes have received increasing attention in recent years as an important substance for intercellular communication. Among the plethora of new research is their unique interaction with drugs is even more striking. Exosomes play essential roles in disease treatment either as extracellular vesicles to exert biological functions or as drug carriers to deliver therapeutic agents. We summarized the relationship between exosomes and drugs in the disease progression and treatment. Understanding how exosomes interact with drugs and exert their anti-inflammatory and pro-angiogenic effects, alongside a lipid peroxidation inhibitory result in different manners is essential for disease treatment.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78032966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Therapeutic Effects of Ligustrazine in Combination with Other Drugs in Cardiovascular Diseases","authors":"Peihua Dong, Yu Huang, Y. Pu","doi":"10.53941/ijddp.0201005","DOIUrl":"https://doi.org/10.53941/ijddp.0201005","url":null,"abstract":"Review\u0000The Therapeutic Effects of Ligustrazine in Combination with Other Drugs in Cardiovascular Diseases\u0000\u0000Peihua Dong , Yu Huang , and Yujie Pu ,*\u0000\u0000\u0000Department of Biomedical Sciences, City University of Hong Kong, Hong Kong 518057 , China\u0000* Correspondence: yujiepu@cityu.edu.hk\u0000 \u0000 \u0000Received: 29 December 2022\u0000Accepted: 18 January 2023\u0000Published: 10 February 2023\u0000 \u0000\u0000Abstract: Chuanxiong, one of the traditional Chinese medicines (TCM), was first documented in the Tang dynasty to promote blood circulation and remove blood stasis. Ligusticum chuanxiong Hort was shown as the most effective portion of chuanxiong. Later chemical analysis revealed that the main chemical component of ligusticum chuanxiong Hort is tetramethylpyrazine. Since then, numerous explorations have been made to examine the efficiency of tetramethylpyrazine in treating different diseases and understand the underlying mechanisms of its action. Like Chuanxiong, ligustrazine (Chuan Xiong Qin) improved the functions of the circulatory and nervous systems. Ligustrazine (Chuan Xiong Qin) was also used in combination with other medicines to achieve better effects on improving cardiovascular health or alleviating the adverse effects of chemotherapies in both basic and clinical studies. The present review briefly summarizes the existing studies of the combination of ligustrazine (Chuan Xiong Qin) with other medicines in the treatment of cardiovascular diseases (CVDs) and provides valuable insights into the future research direction and better utilization of this drug.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81945550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Clinical Successes in Liposomal Nanomedicines","authors":"Wenjie Gu, G. Andrews, Yiwei Tian","doi":"10.53941/ijddp.0201009","DOIUrl":"https://doi.org/10.53941/ijddp.0201009","url":null,"abstract":"Review\u0000Recent Clinical Successes in Liposomal Nanomedicines\u0000\u0000Wenjie Gu , Gavin P. Andrews , and Yiwei Tian , *\u0000\u0000\u0000School of Pharmacy, Queen’s University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK.\u0000* Correspondence: y.tian@qub.ac.uk\u0000 \u0000 \u0000Received: 19 December 2022\u0000Accepted: 26 January 2023\u0000Published: 3 February 2023\u0000 \u0000\u0000Abstract: The intrinsic limitations of cancer therapies promoted the development of safer liposomal nanocarriers capable of better distributing the payload away from normal tissues. Since then, liposomal nanocarriers have been considered the primary drug delivery system for many active pharmaceutical ingredients. These systems are now frequently investigated for the treatment of many infectious diseases. Along with the tremendous progress in the anticancer and antifungal liposomal nanomedicines, we have also gradually realised the difficulties associated with the existing liposomal nanocarrier designs. A better understanding of the nanocarrier-bio interactions may provide a new paradigm in liposomal nanocarrier design and better clinical endpoint efficacy. This short review focuses on the progress and benefits of two market-approved liposomal nanomedicines for cancer and fungal treatments.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90898689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"23-Hydroxybetulinic Acid, A Natural Compound, Alleviates DSS-induced Colitis by Regulating NF-κB Signaling","authors":"Shuangli Xiang, Miaojuan Wang, Xiuping Chen","doi":"10.53941/ijddp.0201007","DOIUrl":"https://doi.org/10.53941/ijddp.0201007","url":null,"abstract":"Article\u000023-Hydroxybetulinic Acid, A Natural Compound, Alleviates DSS-induced Colitis by Regulating NF-κB Signaling\u0000\u0000Shuangli Xiang 1, # , Miaojuan Wang 2, # , and Xiuping Chen 2, *\u0000\u0000\u00001 Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou Province, China.\u00002 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao, China.\u0000* Correspondence: xpchen@um.edu.mo, Tel.: +853-88224679, Fax: +853-28841358\u0000# Co-First author.\u0000 \u0000 \u0000Received: 8 November 2022\u0000Accepted: 2 December 2022\u0000Published: 11 January 2023\u0000 \u0000\u0000Abstract: Ulcerative colitis (UC), an inflammatory intestinal disease, is a growing epidemic affecting people worldwide and requires the development of effective therapeutic drugs. In this study, the effect of 23-hydroxybetulinic acid (23-HBA), a compound isolated from the traditional herb Pulsatilla chinensis (Bunge) Regel, on experimental UC was studied. C57BL/6J male mice were administrated with 3% dextran sodium sulfate (DSS) in drinking water to establish the UC model. 23-HBA was orally administrated at either 3.75, 7.5, or 15 mg/kg for 6 days. Mesalazine was used as a positive control. Examination of the body weight, colon length, disease activity index (DAI), histopathology examination, inflammatory cytokines, oxidative stress, and protein expression was performed. The pathological changes were examined with hematoxylin and eosin (H&E) and Aixian blue-glycogen (AB-PAS) staining. In cultured RAW 264.7 cells, the effects of 23-HBA on lipopolysaccharide (LPS)-stimulated cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and oxidative stress were analyzed. Compared with the colitis model, 23-HBA treatment significantly increased the body weight and colon length and decreased the DAI score. Pathological staining showed that 23-HBA mitigated the damage in intestinal structures, the increase in inflammatory cell infiltration, the increase in submucosa edema, and the decrease in goblet cell number. Furthermore, 23-HBA decreased IL-1β, IL-6, and MDA levels in the colon tissues. In addition, 23-HBA inhibited the protein expressions of COX-2, iNOS, and NF-κB p65 both in the colon tissues and in LPS-stimulated RAW 264.7 cells. In conclusion, these results showed that 23-HBA alleviated DSS-induced acute UC in mice and inhibited LPS-stimulated inflammation in RAW 264.7 cells possibly mediated by regulating the NF-κB pathway.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81265558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hippo Signaling: Advances in Potential Therapeutic Targets for Sinoatrial Node Disorders.","authors":"Julianna N Quinn, Jun Wang","doi":"10.53941/ijddp.2023.100014","DOIUrl":"10.53941/ijddp.2023.100014","url":null,"abstract":"<p><p>The cardiac conduction system (CCS) propagates electrical impulses, generates cardiac contractions, and ultimately ensures regular heartbeats. Disruptions within the CCS lead to cardiac arrhythmias, which are known to be the leading cause of cardiac-related mortalities in humans. The sinoatrial node (SAN) is a key component of the CCS and functions as the natural cardiac pacemaker to initiate normal cardiac impulse and conduction. The SAN is characterized by significant heterogeneity and contains various cell types, including pacemaker cells that spontaneously generate action potentials to maintain a constant beating rhythm. The fundamental Hippo signaling pathway plays a key role in heart development and regeneration. Recently, the Hippo signaling pathway is indicated as a critical pathway for maintaining SAN homeostasis, suggesting therapeutic targets for SAN disorders. This mini-review focuses on the recent molecular and mechanistic findings of Hippo's involvement in regulating SAN homeostasis and discusses potential new therapeutic targets for SAN pathologies.</p>","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"2 4","pages":"36-43"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension","authors":"Zhitong Zhou, Daowen Wang, Junfang Wu","doi":"10.53941/ijddp.v1i1.175","DOIUrl":"https://doi.org/10.53941/ijddp.v1i1.175","url":null,"abstract":"Review\u0000Role of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension\u0000\u0000Zhitong Zhou, Dao Wen Wang, Junfang Wu *\u0000\u0000\u0000Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.\u0000* Correspondence: Junfang.wu@tjh.tjmu.edu.cn\u0000 \u0000 \u0000Received: 17 October 2022\u0000Accepted: 15 November 2022\u0000Published: 21 December 2022\u0000 \u0000\u0000Abstract: Sodium glucose cotransporter 2 inhibitors (SGLT-2i) are a new class of antidiabetic drugs that act by inhibiting the reabsorption of glucose in the proximal renal tubule, which results in lowering the level of blood and urinary glucose. Besides the glucose-lowing effect, some clinical trials found the benefits of SGLT2i in treating heart failure with or without diabetes. In 2021, SGLT2i were recommended by the European Society of Cardiology in treating of heart failure. Compared to heart failure, hypertension is a common cardiovascular disease with an increasing prevalence globally. There is also clinical evidence indicating that SGLT2i can lower blood pressure. Here we focused on addressing the role of SGLT-2i in treating hypertension and its possible mechanism in this review.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81562045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management","authors":"Minxuan Liu, Chiara Ramponi, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, W. Xiao","doi":"10.53941/ijddp.v1i1.171","DOIUrl":"https://doi.org/10.53941/ijddp.v1i1.171","url":null,"abstract":"Review\u0000Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management\u0000\u0000Minxuan Liu, Chiara Ramponi, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, and Wei Xiao *\u0000\u0000\u0000State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, 222001, China.\u0000* Correspondence: xw_kanion@163.com\u0000 \u0000 \u0000Received: 15 October 2022\u0000Accepted: 2 November 2022\u0000Published: 21 December 2022\u0000 \u0000\u0000Abstract: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the world. Myocardial infraction (MI) as one of the most harmful forms of ischaemic heart disease requires rigorous and tempestive approaches which are not met by current clinical interventions. Nanotechnology has developed promising clinical applications for imaging, diagnostic, gene delivery and tissue engineering, which makes this technology a potential candidate for novel therapeutic delivery approach. This review highlights several recent research reports regarding advances in drug delivery using nanoparticle-based (NP) strategies, as well as future challenges and opportunities.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77250323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}